PFA-100 closure times in preoperative screening in 500 pediatric patients

被引:20
|
作者
Roschitz, Birgit
Thaller, Sigrid
Koestenberger, Martin
Wirnsberger, Andrea
Leschnik, Bettina
Fritsch, Peter
Muntean, Wolfgang
机构
[1] Med Univ Graz, Dept Pediat, A-8036 Graz, Austria
[2] Graz Univ, Dept Sports Sci, Graz, Austria
关键词
paediatric haemostasis; von Willebrand disease; closure time;
D O I
10.1160/TH06-09-0493
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three to five percent of patients undergoing surgery have either an acquired or congenital platelet defect or von Willebrand disease (vWD). The predictive value of preoperative coagulation screening is questionable. PFA-100 is now routinely used in preoperative screening in our pediatric outpatient service. We wanted to assess whether the PFA-100 would help to identify patients with primary haemostatic defects or if the additional use of PFA-100 would add to the problem of unnecessary pathologic preoperative laboratory values resulting in delay of surgical procedure. We investigated 500 children consecutively seen in our outpatient service before surgery. Blood cell count, aPTT, PFA-100 closure times (CT) were done in all patients. If abnormalities were found, the patient was presented to a haemostatic expert. vWF:AG, R:Cof and factorVIII were analysed in all patients with prolonged closure times and APTT values. One hundred twenty-six patients (25.2%) showed abnormalities in APTT and/or PFA-100. Further investigations in 89 of these 126 patients did not yield a specific diagnosis; neither diagnostic criteria for impaired haemostasis were found by questionnaire. None of these 89 patients had a bleeding complication during surgery. Forty-eight patients showed prolonged CTs. Twelve patients with low vWF:AG were detected, 10 of these patients were found by PFA-100. Four of these patients did present with normal APTT values. Our study shows that similar to the APTT the PFA-100 is probably only a good screening method when a haemostatic defect in a patient is clinically likely, especially to screen for VWD, and the test should not be used in general unselective screening.
引用
下载
收藏
页码:243 / 247
页数:5
相关论文
共 50 条
  • [21] Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time
    Williams, MS
    Ng'alla, LS
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 10 (04) : 273 - 280
  • [22] The PFA-100®:: a potential rapid screening tool for the assessment of platelet dysfunction
    Harrison, P
    Robinson, M
    Liesner, R
    Khair, K
    Cohen, H
    Mackie, I
    Machin, S
    CLINICAL AND LABORATORY HAEMATOLOGY, 2002, 24 (04): : 225 - 232
  • [23] Are the bleeding time and PFA-100® useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature?
    Cattaneo, M
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (06) : 890 - 891
  • [24] Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain
    Andrew D. Atiemo
    Ladina S. Ng’Alla
    Dhananjay Vaidya
    Marlene S. Williams
    Journal of Thrombosis and Thrombolysis, 2008, 25 : 173 - 178
  • [25] Closure Times Measured by the Platelet Function Analyzer PFA-100® Are Longer in Neonatal Blood Compared to Cord Blood Samples
    Saxonhouse, Matthew A.
    Garner, Rachel
    Mammel, Lauren
    Li, Qin
    Muller, Keith E.
    Greywoode, Jewel
    Miller, Cindy
    Sola-Visner, Martha
    NEONATOLOGY, 2010, 97 (03) : 242 - 249
  • [26] Determinants of PFA-100 Closure Time: A Genome-Wide Association Study
    Qayyum, Rehan
    Becker, Diane M.
    Faraday, Nauder
    Yanek, Lisa R.
    Suktitipat, Bhoom
    Becker, Lewis
    CIRCULATION, 2010, 122 (21)
  • [27] Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain
    Atiemo, Andrew D.
    Ng'Alla, Ladina S.
    Vaidya, Dhananjay
    Williams, Marlene S.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 25 (02) : 173 - 178
  • [28] Evaluation of platelet function in diabetic patients using the PFA-100™.
    Dwyre, DM
    Rios, D
    Wun, T
    Janatpour, KA
    Gosselin, R
    Larkin, EC
    BLOOD, 2001, 98 (11) : 59B - 59B
  • [29] Evaluation of the PFA-100™ in patients with suspected platelet disorders.
    Davidson, SJ
    Burman, JF
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 90 - 90
  • [30] Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients
    Ziegler, S
    Maca, T
    Alt, E
    Speiser, W
    Schneider, B
    Minar, E
    PLATELETS, 2002, 13 (08) : 493 - 497